ReviewWorld journal of diabetes2025
Anemia risk and mitigation strategies in type 2 diabetic patients: The role of novel antidiabetic agents.
Review in World journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?Medical sciences (Basel, Switzerland) · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anemia is a common yet often overlooked complication in patients with type 2 diabetes mellitus (T2DM), particularly those with chronic kidney disease. It significantly impacts patients' quality of life, cardiovascular health, and treatment outcomes. Despite its high prevalence, current clinical guidelines lack specific recommendations for anemia prevention and management in T2DM, especially in the context of newer antidiabetic therapies. This review explores the potential of emerging antidiabetic medications, such as sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and combined GLP-1-RA/GIP to mitigate anemia risk. Early detection and management of anemia in T2DM patients are crucial for improving glycemic control, reducing cardiovascular morbidity, and enhancing overall treatment outcomes. This review underscores the need for further research to better understand the mechanisms by which these novel therapies influence anemia risk and to integrate these findings into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.